This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hosain, S. Articles by Labar, D. Search for Related Content PubMed PubMed Citation Articles by Hosain, S. Articles by Labar, D. Social Bookmarking                         What's this?

Vagus Nerve Stimulation Treatment for Lennox-Gastaut Syndrome

Comprehensive Epilepsy Center, New York Presbyterian Hospital, Cornell University, New York, NY

Bill Nikalov, PA

Comprehensive Epilepsy Center, New York Presbyterian Hospital, Cornell University, New York, NY

Cynthia Harden, MD

Comprehensive Epilepsy Center, New York Presbyterian Hospital, Cornell University, New York, NY

Mark Li, MD

Division of Neurosurgery, New York Presbyterian Hospital, Cornell University, New York, NY

Richard Fraser, MD

Division of Neurosurgery, New York Presbyterian Hospital, Cornell University, New York, NY

Douglas Labar, MD

Comprehensive Epilepsy Center, New York Presbyterian Hospital, Cornell University, New York, NY

Lennox-Gastaut syndrome is a severe age-specific epilepsy syndrome that presents with medication-resistant seizures in childhood. Antiepileptic drugs are the mainstay of treatment. Nonpharmacologic treatments include corpus callosum section and the ketogenic diet. However, no single treatment is safe and effective. We treated 13 patients with Lennox-Gastaut syndrome between the ages of 4 and 44 years (mean, 16.7 years) with vagus nerve stimulation. During the first 6 months of treatment, vagus nerve stimulation produced a median seizure rate reduction of 52% (range, 0% to 93%; P = .04). At 6 months of follow-up, three patients had a greater than 90% reduction in seizures, two had a greater than 75% reduction, one had a greater than 50% reduction, and six had at least a 25% reduction. One patient did not improve. No patient worsened after initial improvement. Side effects, including hoarseness, coughing, and pain in the throat, were transient and tolerable. No patient discontinued vagus nerve stimulation. Our results suggest that vagus nerve stimulation could be an effective and safe adjunct therapy for the treatment of Lennox-Gastaut syndrome. (J Child Neurol 2000;15:509-512).

Journal of Child Neurology, Vol. 15, No. 8, 509-512 (2000)
DOI: 10.1177/088307380001500803


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. V. Murphy, R. Torkelson, I. Dowler, S. Simon, and S. Hudson Vagal Nerve Stimulation in Refractory Epilepsy: The First 100 Patients Receiving Vagal Nerve Stimulation at a Pediatric Epilepsy Center Arch Pediatr Adolesc Med, June 1, 2003; 157(6): 560 - 564. [Abstract] [Full Text] [PDF]

				J. R. Buchhalter and R. G. Jarrar Therapeutics in Pediatric Epilepsy, Part 2: Epilepsy Surgery and Vagus Nerve Stimulation Mayo Clin. Proc., March 1, 2003; 78(3): 371 - 378. [Abstract] [PDF]

				H. W. ROBERTS The effect of electrical dental equipment on a vagus nerve stimulator's function J Am Dent Assoc, December 1, 2002; 133(12): 1657 - 1664. [Abstract] [Full Text] [PDF]

				P. K. Crumrine Antiepileptic Drug Selection in Pediatric Epilepsy J Child Neurol, February 1, 2002; 17(2_suppl): 2S2 - 2S8. [Abstract] [PDF]

				P. K. Crumrine Lennox-Gastaut Syndrome J Child Neurol, January 1, 2002; 17(1_suppl): S70 - S75. [Abstract] [PDF]